Oncology
Refine Search
Biotechnology
Japanese drugmaker Takeda has launched Fruzaqla (fruquintinib) in its home country. 22 November 2024
Biotechnology
Chinese biopharma CStone Pharmaceuticals has announced a strategic commercial collaboration with Pharmalink Store, a prominent pharmaceutical company based in the United Arab Emirates (UAE). 22 November 2024
Biotechnology
Privately-held US biotech Alloy Therapeutics has announced a strategic collaboration and license agreement with Takeda Pharmaceutical. 21 November 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted accelerated approval of Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use, say the drug’s developer, Jazz Pharmaceuticals. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Biotechnology
Bioplatform company builder Flagship Pioneering has announced its companies Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further developed as treatments for obesity and lung cancer. 20 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Biosimilars
Sweden-based Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development agreement for the former company’s Opdivo (nivolumab) biosimilar candidate. 20 November 2024
Biotechnology
A pair of industry veterans have teamed up to create Jupiter Bioventures, a San Francisco-based biotech venture foundry promised to build bold, science-driven therapeutics companies. 20 November 2024
Biotechnology
The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) says that talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged. 20 November 2024
Biotechnology
German biotech CatalYm has followed up a groundbreaking 2023 with an impressive 2024. 19 November 2024
Biotechnology
US pharma giant Merck & Co today announced positive top-line results from the pivotal Phase III MK-3475A-D77 trial for its mega blockbuster drug Keytruda (pembrolizumab) in subcutaneous form. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Biotechnology
Germany’s Lindis Biotech, a specialist in multi-specific antibody platforms, has announced an exclusive licensing agreement with Pharmanovia, for the commercialization of Korjuny (catumaxomab). 19 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Biotechnology
US biotech Rigel Pharmaceuticals and Forma Therapeutics have entered into an exclusive, worldwide license agreement to develop, manufacture and commercialize olutasidenib, an oral, small molecule inhibitor of mIDH1 being investigated for the treatment of relapsed/refractory acute myeloid leukemia (R/R AML) and other malignancies. 3 August 2022
Pharmaceutical
Context Therapeutics, a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, and the Menarini Group have announced a clinical trial collaboration and supply agreement for the latter firm’s oral selective estrogen receptor degrader, elacestrant. 2 August 2022
Biotechnology
Oncology-focused Australian drug development company Kazia Therapeutics lost more than 50% of its stock market value on Monday. 2 August 2022
Biotechnology
USA-based clinical-state biopharma firm IDRx, which is dedicated to transforming cancer treatment with purpose-built precision combination therapies, launched today with a $122 million oversubscribed Series A financing. 2 August 2022
Biotechnology
GluBio Therapeutics, a Sino-American biotech developing novel targeted protein degradation (TPD) drugs, has completed a Series A+ financing of $22 million. 2 August 2022
Pharmaceutical
Scientists at the Russian Granov Scientific Center for Radiology and Surgical Technologies have developed a new drug, which could be recommended for the use against severe forms of cancer, reports The Pharma Letter’s local correspondent. 2 August 2022
Biotechnology
OriCell Therapeutics has announced the completion of Series B financing totaling more than $120 million, which was jointly led by Qiming Venture Partners and Quan Capital. 2 August 2022
Biotechnology
German independent research institute BioMed X has announced the start of its new research project ‘Extrachromosomal DNA in Cancer’ (EDC) in collaboration with the healthcare business of Germany’s Merck KGaA. 1 August 2022
Biotechnology
France-based Innate Pharma today announced that a planned futility interim analysis of the INTERLINK-1 Phase III study sponsored by AstraZeneca did not meet a pre-defined threshold for efficacy. 1 August 2022
Pharmaceutical
US pharma major AbbVie’s shares were up 1.5% at $147.50 pre-market, as it announced financial results for the second quarter ended June 30, 2022. 29 July 2022
Biotechnology
US pharma major Bristol Myers Squibb has announced the failure of Part A of the Phase III CheckMate -914 trial, evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab). 29 July 2022
Pharmaceutical
Anglo-Swedish drugmaker AstraZeneca was trading nearly 1% lower in London trading early on Friday afternoon after presenting its latest financial results. 29 July 2022
Biotechnology
US biotech Seagen reported financial results for the second quarter ended June 30, 2022, after markets closed on Thursday. 29 July 2022
Pharmaceutical
US pharma giant Merck & Co recorded second-quarter sales of $14.6 billion, a rise of 28% on the same period in 2021 and well above the FactSet consensus of $13.87 billion. 28 July 2022
Pharmaceutical
Pfizer has recorded the highest quarterly sales in its history. 28 July 2022
Pharmaceutical
Mid-size French pharma company Ipsen was trading 16% higher late on Thursday after presenting its latest financial results. 28 July 2022
Pharmaceutical
Sanofi has upped its full-year 2022 guidance in presenting the group’s second-quarter financial results. 28 July 2022
Biotechnology
USA-based Elevation Oncology today announced that it has entered into an exclusive license agreement with CSPC Megalith Biopharmaceutical, a subsidiary of China’s CSPC Pharmaceutical Group to develop and commercialize EO-3021 (SYSA1801), a differentiated, clinical stage antibody drug conjugate (ADC) targeting Claudin18.2, in all global territories outside Greater China. 28 July 2022
Pharmaceutical
Japanese pharma giant Takeda today announced strong financial results for the first quarter of fiscal year 2022 (period ended June 30, 2022) and is on track to meet its full-year management guidance. 28 July 2022
Pharmaceutical
UK pharma major GSK has presented its first set of financial results since it spun off its consumer health division Haleon earlier this month. 27 July 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze